How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

404 results for

Quinupristin-Dalfopristin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant Enterococcus faecium with a novel quinupristin-dalfopristin resistance mechanism (PubMed)

The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant Enterococcus faecium with a novel quinupristin-dalfopristin resistance mechanism High-throughput sequencing (HTS) has successfully identified novel resistance genes in enterococci and determined clonal relatedness in outbreak analysis. We report the use of HTS to investigate two concurrent outbreaks of glycopeptide-resistant Enterococcus faecium (GRE) with an uncharacterised resistance mechanism (...) to quinupristin-dalfopristin (QD). Seven QD-resistant and five QD-susceptible GRE isolates from a two-centre outbreak were studied. HTS was performed to identify genes or predicted proteins that were associated with the QD-resistant phenotype. MLST and SNP typing on HTS data was used to determine clonal relatedness. Comparative genomic analysis confirmed this GRE outbreak involved two distinct clones (ST80 and ST192). HTS confirmed the absence of known QD resistance genes, suggesting a novel mechanism

Full Text available with Trip Pro

2018 European Journal of Clinical Microbiology & Infectious Diseases

2. Quinupristin-Dalfopristin

Quinupristin-Dalfopristin Quinupristin-Dalfopristin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quinupristin-Dalfopristin (...) Quinupristin-Dalfopristin Aka: Quinupristin-Dalfopristin , Synercid , Streptogramin From Related Chapters II. Indications: Severe Gram Positive Infections -resistant susceptible susceptible III. Mechanism l 50S Ribosome Resistance rare IV. Pharmacokinetics Hepatic clearance predominates Half-life: 1-3 hours (9-10 hours of affect) V. Adverse Effects s or myalgias , or Rash or VI. Drug Interactions: Metabolized by Cytochrome P-450 3A4 Raises serum drug levels of substrates in 3A4 system Follow levels when

2018 FP Notebook

3. Safety of intravitreal quinupristin/dalfopristin in an animal model (PubMed)

Safety of intravitreal quinupristin/dalfopristin in an animal model To determine whether different intravitreal doses of quinupristin/dalfopristin lead to electroretinographic or histological changes in the rabbit retina over one month period after injection.Eighteen New Zealand white rabbits were divided into three treatment groups (groups 1 to 3) and different intravitreal doses of quinupristin/dalfopristin were tested in each group. The right eye was injected with the drug and the left eye (...) (Kruskall-Wallis test, P=0.000). By day 7, no electrical response to light stimuli was recorded in the treated eyes in groups 2 and 3, consistent with severe damage due to retinal toxicity. Light microscopy revealed no significant histopathological changes in the group 1, while rabbits in groups 2 and 3 had signs of granulomatous inflammation in most cases.Intravitreal 0.1 mg/0.1 mL doses of quinupristin/dalfopristin do not lead to electroretinographic or histological signs of retinal toxicity compared

Full Text available with Trip Pro

2016 International journal of ophthalmology

4. Daptomycin-Vancomycin–Resistant Enterococcus faecium Native Valve Endocarditis: Successfully Treated With Off-Label Quinupristin-Dalfopristin (PubMed)

Daptomycin-Vancomycin–Resistant Enterococcus faecium Native Valve Endocarditis: Successfully Treated With Off-Label Quinupristin-Dalfopristin Multidrug-resistant enterococcal nosocomial invasive infections are a rising concern faced by the medical community. Not many options are available to treat these highly virulent organisms. Risk factors for developing these highly resistant organisms include prolonged hospital stay, previous antibiotic use, and immunosuppression. In this article, we (...) report a case of daptomycin-resistant enterococcal native infective endocarditis treated with off-label use of quinupristin-dalfopristin.

Full Text available with Trip Pro

2016 Journal of investigative medicine high impact case reports

5. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China (PubMed)

Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China Quinupristin/dalfopristin (Q/D) is a valuable alternative antibiotic to vancomycin for the treatment of multi-drug resistant Enterococcus faecium infections. However, resistance to Q/D in E. faecium clinical isolates and nosocomial dissemination of Q/D-resistant E. faecium have been reported in several countries and should be of concern.From January 2012 to December 2015, 911 E. faecium

Full Text available with Trip Pro

2016 BMC microbiology

6. Quinupristin-Dalfopristin

Quinupristin-Dalfopristin Quinupristin-Dalfopristin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quinupristin-Dalfopristin (...) Quinupristin-Dalfopristin Aka: Quinupristin-Dalfopristin , Synercid , Streptogramin From Related Chapters II. Indications: Severe Gram Positive Infections -resistant susceptible susceptible III. Mechanism l 50S Ribosome Resistance rare IV. Pharmacokinetics Hepatic clearance predominates Half-life: 1-3 hours (9-10 hours of affect) V. Adverse Effects s or myalgias , or Rash or VI. Drug Interactions: Metabolized by Cytochrome P-450 3A4 Raises serum drug levels of substrates in 3A4 system Follow levels when

2015 FP Notebook

7. Quinupristin and Dalfopristin

Quinupristin and Dalfopristin Quinupristin and Dalfopristin - Infectious Diseases - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / OTHER TOPICS IN THIS CHAPTER Test your knowledge Smallpox Because (...) Loading , PharmD, University of Washington School of Pharmacy Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Quinupristin and dalfopristin are streptogramin , which, like and , inhibit the synthesis of bacterial proteins. Quinupristin/dalfopristin (Q/D) is given together in a fixed 30/70 combination; this combination has synergistic bactericidal activity against the following: and , including strains resistant to other antibiotic classes Some gram-negative sp

2013 Merck Manual (19th Edition)

8. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. (PubMed)

Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. Treatment of chronic or recurrent Staphylococcus aureus infections may require using antibiotics with activity against intracellular multiresistant organisms. Quinupristin/dalfopristin (3:7) has been examined in this context.Quinupristin and dalfopristin were used separately or mixed. Strains used were: (i) methicillin-susceptible and -resistant S. aureus (MSSA (...) and MRSA); (ii) one vat(B) MSSA and msr(A/B) MRSA; (iii) erm(A)+ [MSSA, MRSA, vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA)]; and (iv) one erm(A/B)+ cfr+ MRSA resistant to quinupristin, dalfopristin and their combination. Assessment of activity was determined by: (i) MICs (CLSI method); and (ii) concentration-response curves in broth and after phagocytosis by THP-1 macrophages, with descriptors of the model (Emin) and the pharmacodynamic response [maximal relative

Full Text available with Trip Pro

2010 Journal of Antimicrobial Chemotherapy

19. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design

trials) and daptomycin, tigecycline, ceftaroline, ceftobiprole, quinupristin-dalfopristin, dalbavancin and iclaprim in fewer trials. Most studies allowed other concomitant antibiotics. Most studies were of adult patients and three were of children; 22 were of hospitalised patients. Most studies concentrated on one type of infection. Two independent reviewers performed the study selection. Assessment of study quality Study quality was assessed using a modified Jadad scale with five criteria

Full Text available with Trip Pro

2013 DARE.

20. Relatively high rates of cefotaxime- and ceftriaxone-non-susceptible isolates among group B streptococci with reduced penicillin susceptibility (PRGBS) in Japan. (PubMed)

, as recommended by the CLSI.The rates of non-susceptibility/resistance to ampicillin, cefotaxime, ceftriaxone and levofloxacin for the 80 PSGBS isolates were 0%, 0%, 0% and 30%, respectively, but were 15% (P = 0.0003), 28% (P < 0.0001), 36% (P < 0.0001) and 93% (P < 0.0001) for the 74 PRGBS isolates, respectively. No PRGBS isolates were identified to be non-susceptible to meropenem, doripenem, vancomycin, quinupristin/dalfopristin, daptomycin or linezolid.We found that cefotaxime- and ceftriaxone-non

2019 Journal of Antimicrobial Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>